A Phase 3 interventional study of OPC-34712 + ADT and Placebo + ADT in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 71 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-01-01.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 3rd registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,539 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2011, is one of 23 in phase 3, and was the 17th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
This study's enrollment of 1,539 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712 + ADT Drug: Placebo + ADT
Drug: OPC-34712 + ADT · Drug: Placebo + ADT
Drug: Placebo + ADT
Drug: Placebo + ADT
Drug pages: BrexpiprazoleStudies of BrexpiprazoleBrexpiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + FDA Approved Antidepressant (ADT)
Placebo + FDA Approved Antidepressant (ADT)
Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Baseline and Week 14
Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Baseline and Week 14
Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Set
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Week 8, 9, 10, 11, 12, and 13
Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Per Final Protocol
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Week 8, 9, 10, 11, 12, and 13
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Scores for the Efficacy Sample Set
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
Time frame: Week 11 and Week 14
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in SDS Mean Scores for the Efficacy Sample Per Final Protocol
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
Time frame: Week 11 and Week 14
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Week 11 and Week 14
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set Per Final Protocol
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Week 11 and Week 14
Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression Severity of Illness (CGI-S) for the Efficacy Sample Set
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Weeks 8, 9, 10, 11, 12,13 and 14
Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical CGI-S for the Efficacy Sample Per Final Protocol
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) IDS-SR Total Score for the Efficacy Sample Set
IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms and atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDS-SR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol
The IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDSSR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher scores indicating more severe depression.
Time frame: Baseline and Week 14
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher score indicating more severe depression.
Time frame: Baseline and Week 14
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
Time frame: Baseline and Week 14
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher score indicating worse anxiety symptoms.
Time frame: Baseline and Week 14
Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Set
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Week 8 to Week 14
Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Per Final Protocol
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set
MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol
MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14
Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Set
MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14
Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Per Final Protocol
MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14
Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set
A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14
Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol
A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
Time frame: Weeks, 8, 9, 10, 11, 12, 13, and 14
The study was conducted in 1539 participants at 92 trial sites in 7 countries. United States, Germany, Ukraine, Russia, Hungary, Canada, and Romania.
| Milestone | Single-blind Placebo + ADT | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|---|
| Started | 1532 | 0 | 0 | 0 | 0 |
| Completed | 1277 | 0 | 0 | 0 | 0 |
| Not completed | 255 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 27 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 60 | 0 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 45 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 74 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 39 | 0 | 0 | 0 | 0 |
| Milestone | Single-blind Placebo + ADT | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|---|
| Started | 0 | 226 | 230 | 221 | 0 |
| Completed | 0 | 216 | 210 | 208 | 0 |
| Not completed | 0 | 10 | 20 | 13 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 3 | 9 | 3 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 4 | 7 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 4 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 |
| Milestone | Single-blind Placebo + ADT | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 600 |
| Completed | 0 | 0 | 0 | 0 | 575 |
| Not completed | 0 | 0 | 0 | 0 | 25 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 3 |
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set | -7.65 ± 0.5 | -7.98 ± 0.51 | -6.45 ± 0.51 |
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol | -7.64 ± 0.52 | -8.29 ± 0.53 | 6.33 ± 0.53 |
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -3.25 ± 0.3 | -2.53 ± 0.3 | -2.19 ± 0.31 |
| Week 10 | -5.34 ± 0.38 | -4.8 ± 0.38 | -3.91 ± 0.39 |
| Week 11 | -6.25 ± 0.41 | -5.56 ± 0.41 | -4.85 ± 0.41 |
| Week 12 | -7.08 ± 0.43 | -6.8 ± 0.44 | -5.52 ± 0.44 |
| Week 13 | -7.55 ± 0.46 | -7.73 ± 0.46 | -6.04 ± 0.47 |
The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -3.09 ± 0.31 | -2.6 ± 0.31 | -2.18 ± 0.32 |
| Week 10 | -5.12 ± 0.39 | -4.92 ± 0.39 | -3.95 ± 0.4 |
| Week 11 | -6.22 ± 0.42 | -5.76 ± 0.43 | -4.86 ± 0.43 |
| Week 12 | -7.09 ± 0.45 | -7.11 ± 0.45 | -5.48 ± 0.46 |
| Week 13 | -7.56 ± 0.47 | -8.05 ± 0.48 | -5.93 ± 0.49 |
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 11 | -1.13 ± 0.13 | -0.67 ± 0.13 | -0.58 ± 0.11 |
| Week 14 | -1.33 ± 0.14 | -1.21 ± 0.13 | -0.84 ± 0.13 |
The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 11 | -1.11 ± 0.13 | -0.74 ± 0.13 | -0.53 ± 0.14 |
| Week 14 | -1.27 ± 0.15 | -1.26 ± 0.15 | -0.78 ± 0.15 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Work/school: Week 11 | -1.00 ± 0.16 | -0.18 ± 0.18 | -0.55 ± 0.15 |
| Work/school: Week 14 | -1.16 ± 0.17 | -0.91 ± 0.18 | -0.73 ± 0.17 |
| Social life: Week 11 | -1.13 ± 0.14 | -0.76 ± 0.14 | -0.72 ± 0.14 |
| Social life: Week 14 | -1.39 ± 0.15 | -1.31 ± 0.15 | -0.91 ± 0.15 |
| Family life: Week 11 | -1.14 ± 0.14 | -0.74 ± 0.14 | -0.51 ± 0.12 |
| Family life: Week 14 | -1.35 ± 0.15 | -1.28 ± 0.16 | -0.80 ± 0.15 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Work/school: Week 11 | -1.01 ± 0.18 | -0.20 ± 0.20 | -0.48 ± 0.19 |
| Work/school: Week 14 | -1.11 ± 0.20 | -0.93 ± 0.21 | -0.65 ± 0.20 |
| Social life: Week 11 | -1.11 ± 0.15 | -0.82 ± 0.15 | -0.68 ± 0.15 |
| Social life: Week 14 | -1.34 ± 0.16 | -1.37 ± 0.16 | -0.88 ± 0.17 |
| Family life: Week 11 | -1.17 ± 0.14 | -0.89 ± 0.15 | -0.54 ± 0.15 |
| Family life: Week 14 | -1.32 ± 0.16 | -1.39 ± 0.16 | -0.81 ± 0.16 |
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -0.25 ± 0.03 | -0.22 ± 0.03 | -0.16 ± 0.03 |
| Week 10 | -0.52 ± 0.05 | -0.46 ± 0.05 | -0.31 ± 0.05 |
| Week 11 | -0.64 ± 0.05 | -0.51 ± 0.05 | -0.44 ± 0.05 |
| Week 12 | -0.73 ± 0.05 | -0.72 ± 0.05 | -0.59 ± 0.05 |
| Week 13 | -0.78 ± 0.06 | -0.77 ± 0.06 | -0.66 ± 0.06 |
| Week 14 | -0.86 ± 0.06 | -0.9 ± 0.06 | -0.75 ± 0.06 |
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -0.24 ± 0.03 | -0.23 ± 0.03 | -0.16 ± 0.03 |
| Week 10 | -0.5 ± 0.05 | -0.47 ± 0.05 | -0.33 ± 0.05 |
| Week 11 | -0.64 ± 0.05 | -0.53 ± 0.05 | -0.45 ± 0.05 |
| Week 12 | -0.73 ± 0.06 | -0.74 ± 0.06 | -0.58 ± 0.06 |
| Week 13 | -0.77 ± 0.06 | -0.8 ± 0.06 | -0.64 ± 0.06 |
| Week 14 | -0.87 ± 0.06 | -0.92 ± 0.06 | -0.72 ± 0.06 |
IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms and atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDS-SR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -3.58 ± 0.41 | -2.68 ± 0.42 | -2.31 ± 0.42 |
| Week 10 | -4.97 ± 0.49 | -4.00 ± 0.5 | -3.11 ± 0.5 |
| Week 11 | -5.83 ± 0.56 | -4.15 ± 0.56 | -3.74 ± 0.57 |
| Week 12 | -6.33 ± 0.59 | -5.77 ± 0.59 | -4.43 ± 0.6 |
| Week 13 | -6.96 ± 0.63 | -6.62 ± 0.63 | -5.66 ± 0.64 |
| Week 14 | -7.02 ± 0.66 | -6.94 ± 0.66 | -5.42 ± 0.67 |
The IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDSSR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | -3.27 ± 0.42 | -2.65 ± 0.42 | -2.15 ± 0.43 |
| Week 10 | -4.7 ± 0.51 | -4.13 ± 0.51 | -2.94 ± 0.52 |
| Week 11 | -5.77 ± 0.57 | -4.29 ± 0.58 | -3.46 ± 0.59 |
| Week 12 | -6.33 ± 0.61 | -6.05 ± 0.61 | -4.18 ± 0.63 |
| Week 13 | -6.88 ± 0.64 | -6.97 ± 0.64 | -5.25 ± 0.66 |
| Week 14 | -6.97 ± 0.67 | -7.2 ± 0.68 | -5.07 ± 0.69 |
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher scores indicating more severe depression.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set | -5.47 ± 0.36 | -6.14 ± 0.36 | -4.8 ± 0.37 |
The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher score indicating more severe depression.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol | -5.36 ± 0.37 | -6.26 ± 0.38 | -4.57 ± 0.39 |
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set | -3.43 ± 0.31 | -3.89 ± 0.31 | -3.33 ± 0.32 |
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher score indicating worse anxiety symptoms.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol | -3.35 ± 0.32 | -3.96 ± 0.33 | -3.07 ± 0.33 |
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 3.36 ± 0.68 | 3.4 ± 0.75 | 3.51 ± 0.67 |
| Week 10 | 3.08 ± 0.85 | 3.09 ± 0.85 | 3.34 ± 0.85 |
| Week 11 | 2.91 ± 0.82 | 2.99 ± 0.89 | 3.17 ± 0.88 |
| Week 12 | 2.78 ± 0.87 | 2.81 ± 0.95 | 3.02 ± 0.95 |
| Week 13 | 2.72 ± 0.87 | 2.73 ± 1.01 | 2.97 ± 1.00 |
| Week 14 | 2.69 ± 0.89 | 2.66 ± 1.1 | 2.85 ± 1.01 |
The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 3.39 ± 0.65 | 3.42 ± 0.74 | 3.54 ± 0.65 |
| Week 10 | 3.1 ± 0.82 | 3.08 ± 0.84 | 3.35 ± 0.84 |
| Week 11 | 2.93 ± 0.8 | 2.99 ± 0.89 | 3.19 ± 0.86 |
| Week 12 | 2.8 ± 0.86 | 2.81 ± 0.94 | 3.06 ± 0.94 |
| Week 13 | 2.75 ± 0.86 | 2.72 ± 1 | 3.01 ± 0.96 |
| Week 14 | 2.71 ± 0.88 | 2.65 ± 1.09 | 2.9 ± 0.99 |
MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 4.5 | 0.45 | 2.8 |
| Week 10 | 10.2 | 6.19 | 5.05 |
| Week 11 | 13.3 | 10.6 | 8.72 |
| Week 12 | 16.9 | 15.5 | 10.1 |
| Week 13 | 18.2 | 18.6 | 15.6 |
| Week 14 | 23.1 | 22.1 | 15.1 |
MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 3.37 | 0.48 | 3.02 |
| Week 10 | 7.58 | 6.1 | 4.93 |
| Week 11 | 13.3 | 11.3 | 8.37 |
| Week 12 | 16.6 | 16.4 | 10.3 |
| Week 13 | 18 | 19.2 | 14.3 |
| Week 14 | 23.2 | 23 | 14.3 |
MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 3.15 | 0.45 | 2.8 |
| Week 10 | 4 | 2.65 | 4.13 |
| Week 11 | 8.44 | 6.19 | 5.5 |
| Week 12 | 11.1 | 8.85 | 5.96 |
| Week 13 | 10.7 | 12.8 | 9.17 |
| Week 14 | 15.1 | 13.7 | 11.9 |
MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 1.92 | 0.48 | 3.02 |
| Week 10 | 2.37 | 2.82 | 3.94 |
| Week 11 | 8.06 | 6.57 | 5.42 |
| Week 12 | 10.4 | 9.39 | 6.4 |
| Week 13 | 9.95 | 13.1 | 8.37 |
| Week 14 | 14.7 | 14.1 | 10.8 |
A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 9.46 | 10.4 | 6.54 |
| Week 10 | 23.6 | 23 | 13.3 |
| Week 11 | 28.4 | 30.1 | 21.6 |
| Week 12 | 35.1 | 38.1 | 29.4 |
| Week 13 | 40 | 43.4 | 28.9 |
| Week 14 | 41.8 | 47.8 | 36.7 |
A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
| Percentage of participants | Brexpiprazole (1mg) + ADT | Brexpiprazole (3mg) + ADT | Placebo + ADT |
|---|---|---|---|
| Week 9 | 7.69 | 9.52 | 5.53 |
| Week 10 | 21.8 | 23 | 12.3 |
| Week 11 | 27.5 | 30 | 19.7 |
| Week 12 | 34.1 | 38 | 27.6 |
| Week 13 | 38.9 | 44.1 | 27.1 |
| Week 14 | 41.2 | 48.4 | 34 |
Collected over AEs were captured from randomization to double-blind treatment at Week 8 to Follow-up 30 (+ 2) days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole (1mg + ADT) | — | 1/226 (0.4%) | 63/226 (27.9%) |
| Brexpiprazole (3mg + ADT) | — | 1/229 (0.4%) | 72/229 (31.4%) |
| Placebo + ADT | — | 0/220 (0%) | 29/220 (13.2%) |
| Event | Brexpiprazole (1mg + ADT) | Brexpiprazole (3mg + ADT) | Placebo + ADT |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/226 | 0/229 | 0/220 |
| EpilepsyNervous system disorders | 0/226 | 1/229 | 0/220 |
| Event | Brexpiprazole (1mg + ADT) | Brexpiprazole (3mg + ADT) | Placebo + ADT |
|---|---|---|---|
| AkathisiaNervous system disorders | 10/226 | 31/229 | 5/220 |
| HeadacheNervous system disorders | 21/226 | 14/229 | 17/220 |
| NasopharyngitisInfections and infestations | 15/226 | 7/229 | 4/220 |
| Weight increasedInvestigations | 15/226 | 13/229 | 2/220 |
| SomnolenceNervous system disorders | 9/226 | 13/229 | 1/220 |
| TremorNervous system disorders | 9/226 | 12/229 | 7/220 |
| Age, Continuous(Years) | Brexpiprazole (1mg + ADT) | Brexpiprazole (3mg + ADT) | Placebo + ADT | Total |
|---|---|---|---|---|
| Mean | 45.7 ± 11.6 | 44.5 ± 11.2 | 46.6 ± 11.0 | 45.6 ± 11.3 |
| Sex: Female, Male(Participants) | Brexpiprazole (1mg + ADT) | Brexpiprazole (3mg + ADT) | Placebo + ADT | Total |
|---|---|---|---|---|
| Female | 158 | 156 | 146 | 460 |
| Male | 68 | 74 | 75 | 217 |
The record gives a start of Jun 2011, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 2 years 5 months after primary completion. A results delay was requested in Oct 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Antiandrogens
Otsuka Pharmaceutical Development & Commercialization, Inc. →